Abstract 2427
Background
Prostate cancer is the most common malignant tumor in men and is the second leading cause of cancer-related deaths in men. Recently there are several 2nd generations of anti-androgen therapies approved and used widely in clinics. However, many patients (pts) relapse after a period of treatment in clinic due to various resistant mechanisms and require new drug or additional therapy. GT0918 is a new chemical entity of androgen receptor (AR) antagonist with more specificity and activity in inhibiting ARs with reduced drug accumulation in the CNS and also show activities on AR mutations including ART878A leading AR drug resistance in cell assays. In early phase I clinical trial of dose escalation study (NCT02826772), GT0918 was shown well tolerated in mCRPC pts progressed lines of standard and experimental therapies with some durable responses. 400mg and 500mg orally once daily were selected warranted for further clinical testing.
Trial design
The study is an open-label, randomized, multicenter, trial to assess GT0918 in mCRPC pts progressed after either abi or enza. The primary object is to evaluate the safety and tolerability of GT0918 either 400 mg or 500 mg daily dose to determine the RP2D for Ph III and/or other confirming studies. The secondary objectives are to evaluate efficacy endpoints including≥ 50% PSA suppression, the percentage of radiographic disease progression, the time to radiographic and bone progression, the time to PSA progression. The key eligibility includes histologically confirmed mCRPC, prior failed therapy either abi or enza (only 1 prior chemotherapy is allowed), progression defined by PCWG 3 criteria, and life expectancy of ≥ 6 months (at screening). 60 pts are enrolled at 12 US sites and randomized in a 1:1 ratio to orally take 400 mg or 500 mg of GT0918 once daily for initial treatment of 6 months. Pts will continue treatment with GT0918 up to 12 months at their assigned dose until disease progression, intolerable toxicities (AEs), or withdrawn consent. The trial started in May 2019. An interim analysis of both safety and efficacy will be performed after 30 pts become evaluable.
Clinical trial identification
NCT03899467 (April 2, 2019).
Editorial acknowledgement
Legal entity responsible for the study
Suzhou Kintor Pharmaceuticals Inc.
Funding
Suzhou Kintor Pharmaceuticals Inc.
Disclosure
N.J. Vogelzang: Advisory / Consultancy: Pfizer; Advisory / Consultancy: Janssen; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Bayer. P. Zhang: Full / Part-time employment: Suzhou Kintor Pharmaceuticals Inc. K. Zhou: Full / Part-time employment: Suzhou Kintor Pharmaceuticals Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2262 - Real world experience of Nivolumab therapy in Metastatic Renal Cancer patients: a 3 year multi-centre review
Presenter: Joanna Hack
Session: Poster Display session 3
Resources:
Abstract
4441 - “A pilot study of tremelimumab (treme) with or without cryoablation (cryo) in patients (pts) in metastatic renal cell carcinoma (mRCC).”
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
2613 - Lenvatinib (Len) alone or in combination with Everolimus (Eve) in heavily pretreated patients (pts) with metastatic renal cell carcinoma (mRCC) after immune checkpoint inhibitors (ICI) and VEGFR-targeted therapies: A single-institution experience
Presenter: Andrew Wiele
Session: Poster Display session 3
Resources:
Abstract
3249 - Weight loss is an underestimated adverse event with cabozantinib in patients with metastastic renal cell carcinoma (mRCC).
Presenter: Emeline Colomba
Session: Poster Display session 3
Resources:
Abstract
2405 - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma.
Presenter: Felix Lefort
Session: Poster Display session 3
Resources:
Abstract
4020 - Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma
Presenter: Carolina Alves Costa Silva
Session: Poster Display session 3
Resources:
Abstract
2407 - Long term relative survival (RS) in patients with primary metastatic kidney cancer (primary mRCC): an analysis of 2,167 patients from the Austrian National Cancer Registry (ANCR).
Presenter: Monika Hackl
Session: Poster Display session 3
Resources:
Abstract
2470 - Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany
Presenter: Peter Goebell
Session: Poster Display session 3
Resources:
Abstract
1533 - Are immune checkpoint inhibitors a valid option for papillary Renal Cell Carcinoma? Transcriptomic characterization of the immune infiltrate
Presenter: Manon De Vries-brilland
Session: Poster Display session 3
Resources:
Abstract
3367 - Treatment-Free Survival, With and Without Toxicity, as a Novel Outcome Applied to Immuno-Oncology Agents in Advanced Renal Cell Carcinoma
Presenter: Meredith Regan
Session: Poster Display session 3
Resources:
Abstract